Cardioprotective effect of the PPAR ligand tetradecylthioacetic acid in type 2 diabetic mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 6, 2011, Pages

  Khalid, Ahmed M ^a   Hafstad, Anne Dragøy ^a   Larsen, Terje S ^a   Severson, David L ^c   Boardman, Neoma ^a   Hagve, Martin ^a   Berge, Rolf K ^b   Aasum, Ellen ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cardiac efficiency; Cardiac function; Cardiac metabolism; Diabetic cardiomyopathy; Ischemia reperfusion

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; FATTY ACID; PEROXISOME PROLIFERATOR; TETRADECYLTHIOACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; HEART MUSCLE METABOLISM; HEART PROTECTION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT; FATTY ACIDS; HEART; HYPERLIPIDEMIAS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SULFIDES;

EID: 79958070133     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00357.2010     Document Type: Article

References (41)

1. Aasum E, Belke DD, Severson DL, Riemersma R, Cooper M, Andreassen M, Larsen TS. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-α activator. Am J Physiol Heart Circ Physiol 283: H949-H957, 2002.
2. Aasum E, Cooper M, Severson DL, Larsen TS. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 83: 183-190, 2005.
3. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52: 434-441, 2003.
4. Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK, Larsen TS. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol 44: 201-209, 2008.
5. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291: H1489-H1506, 2006.
6. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 13: 295-304, 2002.
7. Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA, Skorve J. The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie 87: 15-20, 2005.
8. Boardman NT, Hafstad AD, Larsen T, Severson D, Aasum E. Increased O2 cost of basal metabolism and excitation-contraction coupling in hearts from type 2 diabetic mice. Am J Physiol Heart Circ Physiol 296: H1373-H1379, 2009.
9. Bonen A, Holloway GP, Tandon NN, Han XX, McFarlan J, Glatz JF, Luiken JJ. Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol 297: R1202-R1212, 2009.
10. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, Abel ED. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56: 2457-2466, 2007.
11. Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjoquist PO, Pernow J. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/ Akt and NO pathway. Am J Physiol Heart Circ Physiol 296: H719-H727, 2009.
12. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734: 112-126, 2005.
13. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 8: 65-73, 1994.
14. Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 73: 269-277, 2007.
15. Gnaiger E. Bioenergetics at low oxygen: dependence of respiration and phosphorylation on oxygen and adenosine diphosphate supply. Respir Physiol 128: 277-297, 2001.
16. Greer JJ, Ware DP, Lefer DJ. Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 290: H146-H153, 2006.
17. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
18. Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen TS, Severson DL, Clarke K, Berge RK, Aasum E. Cardiac PPARalfa activation causes increased fatty acid oxidation, reducing efficiency and post-ischemic functional loss. Cardiovasc Res 83: 519-526, 2009.
19. Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E. Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab 292: E1288-E1294, 2007.
20. Holloway GP, Snook LA, Harris RJ, Glatz JF, Luiken JJ, Bonen A. In obese Zucker rats, lipids accumulate in the heart despite normal mitochondrial content, morphology and long-chain fatty acid oxidation. J Physiol 589: 169-180, 2011.
21. How OJ, Aasum E, Kunnathu S, Severson DL, Myhre ES, Larsen TS. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol 288: H2979-H2985, 2005.
22. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55: 466-473, 2006.
23. How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, Boardman NT, Cole M, Clarke K, Severson DL, Aasum E. Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 113: 211-220, 2007.
24. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62: 135-144, 2004.
25. Lovas K, Rost TH, Skorve J, Ulvik RJ, Gudbrandsen OA, Bohov P, Wensaas AJ, Rustan AC, Berge RK, Husebye ES. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. Diabetes Obes Metab 11: 304-314, 2009.
26. Madsen L, Guerre-Millo M, Flindt EN, Berge K, Tronstad KJ, Bergene E, Sebokova E, Rustan AC, Jensen J, Mandrup S, Kristiansen K, Klimes I, Staels B, Berge RK. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. J Lipid Res 43: 742-750, 2002.
27. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53: 2366-2374, 2004.
28. Muna ZA, Bolann BJ, Chen X, Songstad J, Berge RK. Tetradecylthioacetic acid and tetradecylselenoacetic acid inhibit lipid peroxidation and interact with superoxide radical. Free Radic Biol Med 28: 1068-1078, 2000.
29. Muna ZA, Gudbrandsen OA, Wergedahl H, Bohov P, Skorve J, Berge RK. Inhibition of rat lipoprotein oxidation after tetradecylthioacetic acid feeding. Biochem Pharmacol 63: 1127-1135, 2002.
30. Myrmel T, Forsdahl K, Larsen TS. Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J Mol Cell Cardiol 24: 855-868, 1992.
31. Pettersen RJ, Salem M, Skorve J, Ulvik RJ, Berge RK, Nordrehaug JE. Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study. J Cardiovasc Pharmacol 51: 410-417, 2008.
32. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14: 263-283, 1998.
33. Seifert EL, Bezaire V, Estey C, Harper ME. Essential role for uncoupling protein-3 in mitochondrial adaptation to fasting but not in fatty acid oxidation or fatty acid anion export. J Biol Chem 283: 25124-25131, 2008.
34. Srere P. Citrate synthase. Methodes Enzymol 13: 3-5, 1969.
35. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2: 10, 2002.
36. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 67: 1045-1052, 1999.
37. Tian Q, Grzemski FA, Panagiotopoulos S, Ahokas JT. Peroxisome proliferator-activated receptor alpha agonist, clofibrate, has profound influence on myocardial fatty acid composition. Chem Biol Interact 160: 241-251, 2006.
38. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, De PA, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034, 2002.
39. Wergedahl H, Berge K, Bohov P, Tronstad KJ, Madsen L, Berge RK. Long term treatment with tetradecylthioacetic acid improves the antioxidant status in obese zucker (fa/fa) rats. Drug Metab Lett 2: 138-145, 2008.
40. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH. Activation of peroxisome proliferator-activated receptoralpha protects the heart from ischemia/reperfusion injury. Circulation 108: 2393-2399, 2003.
41. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97: 1784-1789, 2000.